BRPI0514606A - sais de lercanidipina - Google Patents

sais de lercanidipina

Info

Publication number
BRPI0514606A
BRPI0514606A BRPI0514606-2A BRPI0514606A BRPI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A BR PI0514606 A BRPI0514606 A BR PI0514606A
Authority
BR
Brazil
Prior art keywords
acids
lercanidipine
salts
acid
amorphous
Prior art date
Application number
BRPI0514606-2A
Other languages
English (en)
Inventor
Amadeo Leonardi
Markus Von Raumer
Gianni Motta
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of BRPI0514606A publication Critical patent/BRPI0514606A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SAIS DE LERCANIDIPINA A invenção refere-se a novos sais de adição compostos de lercanidipina e um contra-íon ácido escolhido do grupo consistindo de: (i) ácidos inorgânicos, (ii) ácidos sulfónicos, (iii) ácidos monocarboxílicos, (iv) ácidos dicarboxílicos, (v) ácidos tricarboxílicos, e (vi) sulfonimidas aromáticas, com a condição de que o referido contra-íon ácido não seja ácido clorídrico. Especialmente, são apresentados ambos os sais amorfos e cristalinos de lercanidipina com os ácidos benzeno-sulfónico e naftaleno-l,5-disulfónico, assim como o são os sais amorfos de lercanidipina com vários outros contra-íons ácidos.
BRPI0514606-2A 2004-08-24 2005-08-22 sais de lercanidipina BRPI0514606A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24
PCT/EP2005/009043 WO2006021397A1 (en) 2004-08-24 2005-08-22 Lercanidipine salts

Publications (1)

Publication Number Publication Date
BRPI0514606A true BRPI0514606A (pt) 2008-06-17

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514606-2A BRPI0514606A (pt) 2004-08-24 2005-08-22 sais de lercanidipina

Country Status (19)

Country Link
US (1) US7683179B2 (pt)
EP (1) EP1799644B1 (pt)
JP (1) JP2008510754A (pt)
KR (1) KR20070045351A (pt)
CN (1) CN101048379A (pt)
AR (1) AR050467A1 (pt)
AU (1) AU2005276619B2 (pt)
BR (1) BRPI0514606A (pt)
CA (1) CA2575078A1 (pt)
EA (1) EA011773B1 (pt)
ES (1) ES2462921T3 (pt)
IL (1) IL180905A0 (pt)
MX (1) MX2007002141A (pt)
NO (1) NO20071515L (pt)
NZ (1) NZ553127A (pt)
PE (1) PE20060629A1 (pt)
TW (1) TW200613275A (pt)
WO (1) WO2006021397A1 (pt)
ZA (1) ZA200702364B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA007485B1 (ru) * 2001-02-24 2006-10-27 Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2810839A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
BRPI0713653A2 (pt) 2006-06-12 2012-10-23 Novartis Ag processo para a preparação de sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil ]fenil]-2e-2propenamida
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2049465A2 (en) * 2007-03-14 2009-04-22 Teva Pharmaceutical Industries Ltd. Processes for preparing solid states of o-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
WO2009070311A2 (en) 2007-11-26 2009-06-04 Teva Pharmaceutical Industries Ltd. Crystal forms of o-desmethylvenlafaxine fumarate
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
SI2320740T1 (sl) 2008-08-01 2014-08-29 The Medicines Company Farmacevtski sestavki clevidipina in postopki za izdelavo nizke koncentracije neäśistoäś le-teh
WO2010014234A1 (en) * 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for stabilizing the same
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN107115530A (zh) 2009-11-27 2017-09-01 勃林格殷格翰国际有限公司 基因型糖尿病患者利用dpp‑iv抑制剂例如利拉利汀的治疗
EP2539313A2 (en) * 2010-03-29 2013-01-02 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
CN102971005A (zh) 2010-06-24 2013-03-13 贝林格尔.英格海姆国际有限公司 糖尿病治疗
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Ｍｙｒｏｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 ２－メチル－２－チアゾリンの塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5912351A (en) 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
JP2006504800A (ja) * 2002-10-16 2006-02-09 レコーダチ アイルランド リミテッド リシノプリル／レルカニジピンの組み合わせ治療
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
EP1799644B1 (en) 2014-02-12
NO20071515L (no) 2007-05-22
EP1799644A1 (en) 2007-06-27
WO2006021397A8 (en) 2006-04-27
CA2575078A1 (en) 2006-03-02
ES2462921T3 (es) 2014-05-26
IL180905A0 (en) 2007-07-04
TW200613275A (en) 2006-05-01
EA200700492A1 (ru) 2007-08-31
PE20060629A1 (es) 2006-08-11
MX2007002141A (es) 2007-04-27
WO2006021397A1 (en) 2006-03-02
EA011773B1 (ru) 2009-06-30
KR20070045351A (ko) 2007-05-02
AU2005276619B2 (en) 2009-04-30
JP2008510754A (ja) 2008-04-10
AR050467A1 (es) 2006-10-25
NZ553127A (en) 2009-07-31
ZA200702364B (en) 2008-09-25
CN101048379A (zh) 2007-10-03
US7683179B2 (en) 2010-03-23
US20060047125A1 (en) 2006-03-02
AU2005276619A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
BRPI0514606A (pt) sais de lercanidipina
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BRPI0514543A (pt) sais de metanossulfonato de abiraterona-3-ésteres e recuperação de sais de abiraterona-3-ésteres de solução em éter de terc-butila de metila
PE20141174A1 (es) Compuestos de pirrol como inhibidores de la bomba de protones
BRPI0720525B8 (pt) inibidores de mapk/erk quinase
EP2123636A4 (en) PROCESS FOR THE PREPARATION OF AN AMINOACETYLPYRROLIDINECARBONITRILE DERIVATIVE
RS53503B1 (en) AMORPHIC AND CRYSTAL FORM GENZ 112638 HEMITARTARATE AS A GLYCOSILKERAMIDE SYNTHASIS INHIBITOR
BRPI0500585A (pt) Processo para a sìntese de ivabradina e sais de adição desta com um ácido farmaceuticamente aceitável
CY1112221T1 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
BRPI0607271A2 (pt) sais de valnemulina com ácidos orgánicos
EA201070966A1 (ru) Фолаты, композиции и применение указанных композиций
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
CY1108321T1 (el) Καινοφανη παραγωγα δικαρβοξυλικου οξεος
BRPI0516595A (pt) processo para fabricar um composto, e, composto
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
PE20230377A1 (es) Composicion de acido sulfurico y sus usos
BR0210531A (pt) Derivados de ácido sulfÈnico
BR0116227A (pt) Processo para a preparação de imidazotriazinonas substituìdas por sulfonamida
NO20081207L (no) Isoquinolines as IGF-1R inhibitors
BR0309120A (pt) Compostos com atividade antagonista de integrina alfa4
BR0108990A (pt) Processo para preparação de derivados de pirimidona com atividade antifungos
BRPI0514452A (pt) composições, métodos de fabricação e uso de compostos de guanilhidrazona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.